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Portacaval Shunt and Hyperlipidemia 
Thomas E. Starzl. MD, PhD; Charles W. Putnam. MD; Lawrence J. Koep, MD 
• The use of a completely diverting portacaval shunt for the 
purpose of lowering the serum concentration of cholesterol and 
IOw-denslty lipoproteins Is reviewed and a recommendation 
provided that such a shunt for hyperlipidemia should be consld-
tnId for type II Individuals. 
(Arch Surg 113:71-74, 1978) 
It has been more than four years since completely diverting portacaval shunt was first performed clini-
cally' for the purpose of lowering the serum concentration 
of cholesterol and low-density lipoproteins (LDL). Since 
then, we have treated two more patients with this method. 
An additional nine patients who have undergone the same 
procedure in other centers have been documented in the 
literature. ,., 
These 12 cases represent less than one half of the true 
total. Through an informal registry that has been kept at 
the National Institutes of Health, Bethesda, Md, it is 
known that more than 30 portacaval shunts have been 
carried out for the treatment of hyperlipidemia, with 
resUlts that are in general agreement with the smaller 
IIlInple that is accessible through the formal literature. 
RATIONALE OF PORTAL DIVERSION 
The reasons for proposing portal diversion to lower 
serum lipid levels were simpler than the justifications and 
explanations that have become possible in hindsight. At 
the time we saw our first patient with homozygous type II 
hyPerlipidemia, we had been engaged in a study of children 
lVith glycogen storage disease who were treated with end-
to-side portacaval shunt. Patients with type I glycogenosis 
(gJUcose-6-phosphatase deficiencv) have elevated serum 
lipid levels of all classes. Thev' were noted to' have an 
itnmediate and permanent rem"ission of these abnormali-
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ties after portacaval shunt.' The pragmatic question was 
asked: would the same effect occur after portal diversion in 
patients with hyperlipidemia? Mostly on this basis, the 
operation was carried out. Support for the idea was 
provided from our own laboratory research, but the rele-
vance of this animal work to humans, and particularly to 
homozygous type II hyperlipidemia, was not known. since 
the etiology of this autosomal dominant inherited disorder 
is by no means understood. All three of our patients had 
homozygous type II hyperlipidemia. 
Goldstein and Brown" have suggested that in type II 
hyperlipidemia there may be an absence of, or defect in, 
the cell surface receptor sites that normally bind and 
transport LDL cholesterol into the cell. Because cholesterol 
then does not enter the cell, they suggest that there is an 
absence of the normal feedback suppression of cholesterol 
synthesis. 
Whatever its cause, the homozygous form of type II 
hyperlipoproteinemia has a shockingly poor prognosis if 
there is not a good response to medicinal therapy. Lipid-
rich deposits are laid down in widely separated superficial 
and deep parts of the body, including blood vessels, where 
Fig 1.-Serum cholesterol concentrations after portacaval shunt 
in patient 1. 
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premature atherosclerosi::; is the consequence. Cardiac 
\'ah'es are ~imilarly affected. with aortic stenosis heing 
particularly common. The patients usually die of cardiovas-
cular complications before the age of 20 years. despite all 
conventional therapy. The gravity of this situation justi-
fied the trial of a new approach. which was carried out 
under the appropriate conditions of informed consent. 
EFFECTS OF CLINICAL 
PORTAL DIVERSION 
Colorado Cases 
Our first patient. an ll-year-old girl. had suffered a major 
myocardial infarction ahout two months before undergoinC(' porta-
raval 6hunt. After the portal diversion. hl'r serum rhole~ternl 
values fell from ahout 800 mgllOO ml to levels that were consis-
tently below 400 mg! 100 ml (Fig 1). l'nsightly xanthomas hegan to 
resorb from visible suhcutaneous and tendinous locations I Fig :!1. 
Attacks of preexisting angina pectoris hecame less frequent and· 
finally stopped. By cardiac catheterization 16 months after the 
end-to-side portacaval shunt was performed. there was good 
evidence that re\'ersal of aortic stenosis had occurred. with a 
diminution of the aortic valve gradient from 56 to 10 mm Hg.'" The 
coronary arteries were also thought to be less diseased than 
before. although three stenoses were still present. More than l' ~ 
years after portacaval shunt. the girl died suddenly while 
Fig 2.-Hands of patient 1 two weeks before (left) and 16 months after (right) portacaval shunt. 
Patients With Type" Hyperlipidemia Treated at the University of Colorado. Denver 
Serum Cholesterol 
, 
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Patient I Date of Preshunt, Postlhunt, Final Clinical 
Age. yr Operation mg/l00 ml mg/l00 ml Reduction. % Result Comments 
1112 3/1173 769 290 62 Oied 18V, mo Old myocardial infarct with ventricular 
postoperativel~ aneurysm: residual stenoses of coronary 
of cardiac arteries: xanthomas had disappeared. 
arrest 
217 10/4174 997 450 55 Good Underwent aortic & mitral valve 
replacement plus double coronary artery 
bypass 25 months after shunt: 
xanthomas nearly completely 
disappeared. 
3.'8 8/5175 1000 620 38 Good Xanthomas slowly disappearing 
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Fig 3.-Systemic venous plasma glucose. insulin, and glucagon concentra-
tions in patient 2 with hyperlipidemia, before and after portacaval shunt. 
returning home from school. 
At autopsy, the residual coronary artery disease was confirmed. 
There was a large ventricular aneurysm. The conclusion was that 
death probably was caused by an acute cardiac arrhythmia." The 
patient should have undergone a coronary revascularization proce-
dure, as was done in case 2. The decision against this was 
predicated on the hope that the coronary artery stenoses would 
spontaneously regress. 
The portacaval shunt was widely patent. The liver, which 
Weighed 618 gm, was grossly normal. and microscopically it was 
unchanged from the biopsy specimen that was obtained six 
months postoperatively. On light and electron microscopy, the 
lIlost prominent findings were shrinkage of the hepatocyte size, 
depletion of rough endoplasmic reticulum, and the accumulation of 
intracytoplasmic lipid deposits. These changes are typical of those 
caused in the !i,'er by portacaval shunt in all species studied so 
far." Hepatic function had not been changed by portacaval shunt 
as judged b~D standard !i,'er function tests. 
We have performed a portacaval shunt on two more patients 
With the same diagnosis (cases 2 and 3, Table). Patient 2 was 7 
years old at the time of operation. She had preoperati"e serum 
cholesterol values that averaged 997 ::: 47 (SD) mgilOO ml while on 
& verv low cholesterol diet. Six months after the shunt, the 
~esterollevel measured in the same laboratory was 600 mg/lOO 
lilt (a 40c;;. reduction), despite a relaxation of the diet. These ,'alues 
have continued to fall unaer careful medical management at 
Southwestern Cniversity Medical Center, Dallas. The cholesterol 
eoncentration~ during- the last year haw been 450 '" 67 mg/lOO 
1IlJ. The xanthomas on her heels, eloows, and hands either have 
~rbed completel~D or ha,·e greatly diminished in size. 
This child also had aortic stenosis and angina p~ctorisK Because 
of persistPnce of her cardiac disease, shE' was treated at the Fort 
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Worth (Tex) Children's Hospital with aortic and mitral valve 
replacement plus double coronary artery bypass two years after 
portacaval shunt. The patient has returned to school with essen-
tially unlimited acth·ities. According to her physician, results af 
the operation were as follows: 
Our therapeutic approach continues to be one of trying to get [her] 
cholesterol as" low as possible with medication. I am totally 
convinced that the portacaval shunt was tremendously helpful to 
her. I doubt that we would have proceeded with the cardiac 
surgery if her cholesterol were still in the 900 to 1,000 nlg% range. 
Her present cardiac difficulties are an extension of those already 
present before the shunt surgery. Our main job now is to try and 
retard the development of atherosclerosis in her coronary bypass 
grafts (D. Bilheimer, MD, written communication, May 1977). 
Our third patient has had a reduction in the serum cholesterol 
level from 1,000 to 600 to 650 mgilOO ml in the 21 months 
postoperatively (Table). Although the falls in cholesterol level 
were less striking than in our first two patients, "isible xanthomas 
are slowly resorbing and the patient is asymptomatic almost two 
years postoperatively. Changes in peripheral insulin and glucagon 
content in these patients have been noted. Preoperative values 
were normal. Postoperatively, systemic venous insulin and 
glucagon values were both increased, especially the former 
(Fig 3). 
:'Iione of our three patients with hyperlipidemia has had any 
signs of hepatic encephalopathy. :'Iievertheless, the use of porta-
caval shunt to ameliorate hyperlipidemia accepts a trade-off of 
suboptimal conditions of liver perfusion in return for metabolic 
improvements that are derived from these suboptimal conditions. 
Realization of this fact has prompted us to recommend portacaval 
shunt for this inborn error only if there was a homoz~·gous state. 
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However. the freedom from enl'ephalopathy in our patients 
suggests that symptomatic heterozygous patients who are refrac-
tory to medical therapy should also be considered for portal 
diversion. The patient of Weglicki et aF probably had the hetero-
zygous trait. 
Other Reports 
In the nine cases reported in the literature by others,'"' the 
serum cholesterol level lowerings have been variable from patient 
to patient, as in our three cases. A significant fall was usually 
obtained if the shunt was patent. Cardiac symptoms were often 
relieved and resorption of xanthomas proceeded even if the falls in 
serum cholesterol concentration were not great. The latter finding 
has raised the possibility that cholesterol depots may keep the 
serum cholesterol concentrations high until the resorption is 
nearly complete. Failure to observe an antilipidemic effect has 
been associated with thrombosis of the shunt."'" 
Weglicki et aF have used portacaval shunt and coronary artery 
bypass together in a young patient suffering from premature 
atherosclerosis. This kind of combined therapy will probably be 
used more frequently in the future, as was illustrated also by the 
treatment of our patient 2. 
MECHANISM OF 
PORTAL DIVERSION EFFECT 
The antilipidemic effect of portacaval shunt can be 
demonstrated with a normal starting point of serum 
cholesterol concentration just as easily as with a patholog-
ically high concentration. This was first observed by 
Winter et alii in normal dogs and confirmed in that species 
by Starzl et al," Coyle et aI," Horak et ai,'" and Guzman et 
alY The same has been seen in rats,"'· pigs,'''''' and 
baboons.'" 
Studies in the dog" and investigations in the rat,'""" 
pig/oOl and human"' have shown or suggested that a 
reduction in hepatic cholesterol or LDL synthesis or both is 
responsible at least in part for the falls in cholesterol levels. 
Only the reports of Coyle et ai'· and Guzman et al" in dogs 
have denied this. Other factors may contribute to the 
antilipidemic effect of portal diversion, as Ahrens"' and 
others" have speculated. 
Our experiments in dogs have suggested that the main 
reason for decreased hepatic cholesterol synthesis is depri-
vation of the liver of insulin." One consequence is a 
moderately severe liver injury of the kind described earlier 
in the autopsy findings of patient 2. Eaton"; has recently 
proposed that the changes in glucagon metabolism may be 
important in the antilipidemic effect of portal diversion. 
Further clarification of these mechanisms will be impor-
tant if treatment alternatives to portacaval shunt are to be 
evolved. 
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of Southwestern Cnin-rsity Medical Center. Dallas referred patient 2 and 
suhsequently cared for her. Robert McGehee. :'ID. of Fort Worth ITe,) 
Children's Hospital carried out the cardiac operatIons on patient Z. 
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